ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for a convertible note financing of up to $24 million..

圣路易斯，2026年11月10日（环球电讯社）——微创血管内介入手术机器人领域的先驱和全球领导者Stereotaxis, Inc.（纽约证券交易所代码：STXS）今日宣布，公司已与投资者签订最终协议，进行高达2,400万美元的可转换票据融资。

“We appreciate the confidence and support from several of our long-term shareholders in this oversubscribed financing,” said David Fischel, Chairman and CEO. “Our strengthened balance sheet positions us to execute our strategy and accelerate adoption of our comprehensive portfolio of innovations.”

“我们感谢几位长期股东在这次超额认购融资中给予的信任与支持，”董事长兼首席执行官大卫·菲舍尔表示。“我们强劲的资产负债表使我们能够执行我们的战略，并加速推动我们全面创新产品组合的采用。”

The financing includes an initial upfront closing of $12 million, and an additional $12 million draw available at Stereotaxis’ option following certain regulatory milestones. The notes carry a 10% annual interest rate, with interest accrued and due at maturity in three years. The notes may be converted into common stock at a conversion price of $1.21 per share, a 30% premium to the 10-day volume weighted average price of Stereotaxis’ common stock prior to closing of the financing..

该融资包括1200万美元的初始首笔交割，以及在达成某些监管里程碑后，Stereotaxis可选择额外提取的1200万美元。这些票据年利率为10%，利息累计并在三年到期时支付。这些票据可按每股1.21美元的转换价格转换为普通股，该价格较融资交割前Stereotaxis普通股10日成交量加权平均价格溢价30%。

With this financing, Stereotaxis has $16 million in proforma cash and cash equivalents, with access to an additional $12 million, for total availability of $28 million. The structure of the financing reflects Stereotaxis’ belief that this financing bridges the Company to profitability.

通过此次融资，Stereotaxis 公司的备考现金及现金等价物为 1,600 万美元，并可获得额外 1,200 万美元的资金，总可用资金达 2,800 万美元。该融资结构反映了 Stereotaxis 公司的信念，即此次融资将助力公司实现盈利。

Net proceeds from the financing will be used for working capital, to accelerate product commercialization, research and development, and other general corporate purposes. Additional details on the financing and convertible note securities will be included in the Form 8-K to be filed by Stereotaxis with the Securities and Exchange Commission.

融资所得净额将用于营运资金、加速产品商业化、研发以及其他一般公司用途。关于本次融资及可转换票据证券的更多详情，将包含在 Stereotaxis 向美国证券交易委员会提交的 8-K 表格中。

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful..

本新闻稿不构成出售要约或购买要约的征询，也不构成在任何此类要约、征询或销售属非法的司法管辖区内的要约、征询或销售。

About Stereotaxis

关于 Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room.

Stereotaxis（纽约证券交易所代码：STXS）是微创血管内介入手术创新机器人领域的先驱和全球领导者。其使命是为介入实验室发现、开发和提供机器人系统、器械及信息化解决方案。这些创新帮助医生以机器人级别的精准度和安全性提供卓越的患者护理，扩大微创治疗的可及性，并提升手术室的生产力、连通性和智能化水平。

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .

立体定向技术已用于治疗美国、欧洲、亚洲及其他地区的超过15万名患者。如需更多信息，请访问。

www.stereotaxis.com

www.stereotaxis.com

.

。

This press release includes statements that may constitute 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s convertible note financing, the ability to draw additional funds under the convertible note financing following receipt of required regulatory approvals and the anticipated use of proceeds therefrom, usually containing the words 'believe”, 'estimate”, 'project”, 'expect' or similar expressions.

本新闻稿包含可能构成1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的“前瞻性”陈述的声明，包括关于公司可转换票据融资完成、在获得所需监管批准后根据可转换票据融资提取额外资金的能力以及由此产生的收益的预期用途的声明，通常包含“相信”、“估计”、“预测”、“预期”或类似表述。

Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the Company's ability to manage expenses at sustainable levels; acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology; competitive factors; changes resulting from healthcare policy, dependence upon third-party vendors; timing of regulatory approvals including as it relates to both the products of our recently acquired subsidiary, Robocath, and our ability to make further draws on the convertible note financing, the impact of pandemics or other disasters, statements generally relating to our recent acquisition of Robocath or our recently announced convertible note financing, including any benefits expected from either of those transactions, as well as any plans, forecasts and other expectations with respect to Robocath’s business following the completion of the transaction; and other risks discussed in the Company's periodic and other filings with the SEC.

前瞻性陈述本质上涉及风险和不确定性，可能导致实际结果出现重大差异。导致或促成此类差异的因素包括但不限于与以下方面相关的不确定性：公司将费用控制在可持续水平的能力；市场对公司产品的接受程度；全球经济状况对客户购买其技术的能力和意愿的影响；竞争因素；医疗政策变化带来的影响；对第三方供应商的依赖；监管审批的时间安排，包括涉及公司最近收购的子公司 Robocath 的产品以及公司进一步提取可转换票据融资款项的能力；流行病或其他灾害的影响；通常与公司最近收购 Robocath 或最近宣布的可转换票据融资相关的陈述，包括预计从这些交易中获得的任何收益，以及在交易完成后关于 Robocath 业务的任何计划、预测和其他预期；以及公司在向美国证券交易委员会（SEC）提交的定期报告和其他文件中讨论的其他风险。

By m.

作者：m.

Stereotaxis Contacts:

立体定向接触点：

David L. Fischel

大卫·L·菲谢尔

Chairman and Chief Executive Officer

董事长兼首席执行官

Kimberly Peery

金伯利·皮里

Chief Financial Officer

首席财务官

314-678-6100

314-678-6100

Investors@Stereotaxis.com

Investors@Stereotaxis.com